Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

IMPAX LABORATORIES INC (IPXL)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2013 | 01:35pm CET

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications
www.impaxlabs.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMPAX LABORATORIES INC
01/16 IMPAX LABORATORIES : to Report Fourth Quarter and Full Year 2017 Results on Marc..
01/09 IMPAX LABORATORIES, INC. (NASDAQ : IPXL) Files An 8-K Departure of Directors or ..
01/09 IMPAX LABORATORIES, INC. (NASDAQ : IPXL) Files An 8-K Regulation FD Disclosure
01/09 IMPAX LABORATORIES INC : Regulation FD Disclosure, Financial Statements and Exhi..
01/09 IMPAX LABORATORIES INC : Change in Directors or Principal Officers, Financial St..
01/05 IMPAX LABORATORIES : Amneal Pharmaceuticals and Impax Laboratories to Present at..
01/03 IMPAX LABORATORIES : Amneal Pharmaceuticals and Impax Laboratories to Present at..
2017 IMPAX LABORATORIES INC : ACT NOW: Monteverde & Associates PC Announces An Invest..
2017 IMPAX LABORATORIES INC : Other Events (form 8-K)
2017 IMPAX LABORATORIES : Announces Sale of Taiwan Manufacturing Facility
More news
News from SeekingAlpha
01/19 U.S. Justice Department may seek damages from generic drugmakers for price-fi..
01/19 WALL STREET BREAKFAST : Investors Calm As Government Shutdown Looms
01/18 Generic firms under pressure on possible hospital drug-making venture
01/18 Hospital groups planning to enter generic drugs business
01/16 Is The New Impax/Amneal An Interesting Pairing?
Financials ($)
Sales 2017 791 M
EBIT 2017 97,4 M
Net income 2017 -174 M
Debt 2017 631 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 22,39
EV / Sales 2017 2,69x
EV / Sales 2018 3,42x
Capitalization 1 493 M
Chart IMPAX LABORATORIES INC
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Technical analysis trends IMPAX LABORATORIES INC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 20,8 $
Spread / Average Target 3,5%
EPS Revisions
Managers
NameTitle
Paul M. Bisaro President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Jeffrey D. Nornhold Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
IMPAX LABORATORIES INC22.52%1 493
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132